WHAT IS CLAIMED IS:

1. A pharmaceutical composition useful in alleviating pathological conditions in mammals, comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetyl-cysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract.

10

5

2. The pharmaceutical composition of claim 1, wherein in a dose of the composition contains approximately; 25 mg of lysine, 15 mg of proline, 8 mg of arginine, 80 mg of ascorbic acid, 30 mg of magnesium, 50 mg of green tea extract, 15 mg of N-acetyl-cysteine, 5 mcg of selenium, 50mcg of copper, and 200 mcg of manganese.

15

3. The pharmaceutical composition of claim 1 further comprising one or more of the following substances; Vitamin A, Vitamin D3, Vitamin E, Vitamin B1, Vitamin B2, Niacin, Vitamin B6, Folic Acid, Vitamin B12, Biotin, Pantothenic Acid, Calcium, Phosphorus, Zinc, Chromium, Moylbdenum, Pottasium, Citrus Bioflavonoids, Inositol, L-Carnitine, CoEnzyme Q10, Glucosamine, Taurine, and Chondroitin Sulfate.

20

25

4. The composition of claim 3, wherein one or more of the following substances are persent in approxiamtely the following amounts; 191 IU of Vitamin A, 20 IU of Vitamin D3, 10 IU of Vitamin E, 1.5 mg of Vitamin B1, 1.5 mg of Vitamin B2, 10 mg of Niacin, 1.5 mg of Vitamin B6, 75 mcg of folic acid, 3.3 mcg of Vitamin B12, 10 mcg of Biotin, 5 mg of Pantothenic Acid, 15 mg of Calcium, 2.5 mg of Phosphorus, 2.5 mg of Zinc, 5 mcg of Chromium, 0.5 mcg of Moylbdenum, 5 mg of Pottasium, 15 mg of Citrus Bioflavonoids, 5 mg of Inositol, 5 mg of L-Carnitine, 2.5 mg of CoEnzyme Q10, 25 mg of Glucosamine (N-Acetyl-D-Glucosamine), 50 mg of Taurine, and/or 15 mg of Chondroitin Sulfate.

30

5. The pharmaceutical composition of claim 1 wherein the pathological condition is atherosclerosis, arteriosclerosis.

- 6. The pharmaceutical composition of claim 1, wherein the composition is in a oral form or a parenteral form.
- 7. The pharmaceutical composition of claim 6, wherein the oral form is a tablet, a pill or a capsule.
 - 8. A method for retardation of an inflammatory response in mammals, comprising the step of administering to a mammal in need of treatment an effective amount of the pharmaceutical composition of claim 1.

9. The method of claim 8, wherein the effective amount of the composition is a daily dosage of approximately 0.3 mg/kg lysine, 0.2 mg/kg proline, 0.1 mg/kg arginine, 1.1 mg/kg Vitamin C, 0.4 mg/kg magnesium, 0.7 mg/kg green tea extract, and 0.2 mg/kg N-

acetyl-cysteine.

10

15

30

- 10. The method of claim 8, wherein the pharmaceutical composition is administered orally, intravenously, or parenterally.
- A method for retardation of arteriosclerosis and atherosclerosis in mammals, comprising
 the step of administering to a mammal in need of treatment an effective amount of the pharmaceutical composition of claim 1.
- The method of claim 11, wherein the effective amount of the composition is a daily dosage of approximately 0.3 mg/kg lysine, 0.2 mg/kg proline, 0.1 mg/kg arginine, 1.1
 mg/kg Vitamin C, 0.4 mg/kg magnesium, 0.7 mg/kg green tea extract, and 0.2 mg/kg Nacetyl-cysteine.
 - 13. The method of claim 11, wherein the pharmaceutical composition is administered orally, intravenously, or parenterally.